ArticleWorld journal of surgical oncology2026
Tyrosine kinase inhibitors combined with PD-1 inhibitors reduce peritoneal metastasis risk for patients with ruptured HCC receiving TACE/TAE: a multicenter retrospective study.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate whether the combination of tyrosine kinase inhibitors (TKIs) and PD-1 inhibitors can reduce the risk of peritoneal metastasis (PM) in patients with ruptured hepatocellular carcinoma (HCC) after transcatheter chemoembolization/embolization (TACE/TAE). MATERIALS AND
methodsThis study included 163 patients with ruptured HCC who received TACE/TAE at 4 centers from June 2015 to June 2023. Patients were categorized into two groups based on their treatment: the combination group, which received TKIs plus PD-1 inhibitors, and the TACE/TAE group, which did not. Propensity score matching (PSM) analysis was performed in a ratio of 1:2 to reduce bias between the groups. The PM rate, overall survival (OS) and the occurrence of adverse events were analyzed and compared between the two groups. Moreover, the independent factors associated with PM were further evaluated.
resultsThe median follow-up duration was 801 days [95% confidence interval (CI): 720.2-925.7]. After PSM, the combination and TACE/TAE groups comprised 45 and 90 patients, respectively. A significant difference was observed in the peritoneal PM rate (combination group: 6.7% vs. TACE/TAE group: 23.3%, P = 0.032). The corresponding 3-, 6-, 12-, and 24-month PM cumulative incidence was 5.6%, 15.7%, 22.5%, and 24.1% in the TACE/TAE group, and 0%, 0%, 4.9%, and 7.7% in the combination group, respectively (P < 0.001). The combination group exhibited a significantly longer median OS compared to the TACE/TAE group (OS:566 days vs. 120 days, P < 0.001). The multivariate competing risk analysis identified hepatitis B virus (HBV) infection [subdistribution hazard ratio (SHR), 0.420; 95% CI: 0.188-0.939; P = 0.035), Barcelona Clinic Liver Cancer stage C (BCLC C) (SHR, 0.228; 95% CI: 0.059-0.874; P = 0.031), and combination therapy (SHR, 0.267; 95% CI: 0.082-0.866; P = 0.028) as the independent factors for PM. More adverse events were witnessed in the combination group compared with the monotherapy group, most of which were tolerable and manageable.
conclusionsThe combination of TKIs and PD-1 inhibitors reduced the risk of PM compared with TACE/TAE in patients with ruptured HCC. Also, PM was less likely to occur in patients with HBV-related and BCLC C ruptured HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.